EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials

Jian Li iD, Ting Deng, Yanhong Gu, Antonio Calles Blanco iD, Zhihua Li, Chunmei Bai, Lin Wu iD, Jing Huang, Xingya Li, Yu Yao, Zhengbo Song iD, Yongsheng Li und 20 weitere

Cancer Communications · 2025-11 · 45 (11) · 1500-1512

DOI: 10.1002/cac2.70056 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Communications, online erschienen am 02.10.2025. Verfasst von Jian Li und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Cancer …. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jacobio Pharmaceuticals Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glecirasib, an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine‐to‐cysteine substitution at codon 12 ( KRAS G12C), has exhibited clinical activity in non‐small‐cell lung cancer (NSCLC) and colorectal cancer (CRC). Here, we investigated the efficacy and safety of glecirasib in patients with pancreatic ductal adenocarcinoma (PDAC) and other solid tumors (excluding NSCLC and CRC) that rarely harbor the KRAS G12C mutation but for which effective treatment options remain limited.

Methods

We conducted and analyzed two open‐label, phase I/II trials in adult patients with KRAS G12C mutant solid tumors, in which glecirasib was administered orally. The two trials had similar eligibility criteria and endpoints but differed in the regions of patient recruitment. We performed a pooled analysis of all patients, excluding NSCLC and CRC, from both trials. The primary endpoint in the pooled population was objective response rate (ORR). Efficacy and safety were assessed in patients who received at least one dose of glecirasib.

Results

As of June 30, 2024, the pooled analysis included 54 patients who were treated with glecirasib: 32 PDACs, 8 biliary tract cancers (BTCs), 4 small intestinal cancers, 3 gastric cancers, 2 appendiceal cancers, and 5 other tumors. At baseline, 24 received ≥ two prior lines of systemic therapy. Of the 53 efficacy‐evaluable patients, the confirmed ORR was 50.9% (95% confidence interval [CI], 36.8%‐64.9%), with an ORR of 46.9% (95% CI, 29.1%‐65.3%) in PDAC patients. Among other solid tumors, ORR was 71.4% (5/7) in BTC, 100% (4/4) in small intestinal cancer, and 66.7% (2/3) in gastric cancer. Median progression‐free survival and median overall survival were 6.9 and 10.8 months, respectively, in the overall population, and 5.5 and 10.8 months, respectively, in patients with PDAC. Treatment‐related adverse events (TRAEs) of any grade occurred in 94.4% patients, with grade ≥ 3 TRAEs in 27.8%. No fatal TRAEs or TRAEs leading to treatment discontinuation occurred.

Conclusions

Glecirasib showed promising efficacy and was well tolerated in patients with PDAC and other advanced solid tumors (beyond NSCLC and CRC), warranting further expedited clinical development in this patient population.

Trial registration

ClinicalTrials.gov identifier: NCT05009329 and NCT05002270.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)NeoplasmsHumansMaleMiddle AgedFemaleAgedMutationAdultAged, 80 and overPancreatic NeoplasmsTreatment Outcome

Stichwörter der Autor:innen

JAB‐21822KRAS G12Cbiliary tract cancerglecirasibpancreatic cancersmall intestinal cancer

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing Cancer Hospital, Beijing, P. R. China.
  • Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, P. R. China.
  • Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P. R. China.
  • Department of Medical Oncology, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
  • Department of Medical Oncology, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, P. R. China.
  • Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, P. R. China.

ORCID-Profile: Jian Li, Antonio Calles Blanco, Lin Wu, Zhengbo Song, Ligang Xing, Jian Zhang

Förderung

  • Jacobio Pharmaceuticals Co., Ltd

Zitieren

APA

Li, J., Deng, T., Gu, Y., Calles Blanco, A., Li, Z., Bai, C., Wu, L., Huang, J., Li, X., Yao, Y., Song, Z., Li, Y., Liu, L., Xing, L., Wu, W., Martínez-Pérez, J., Hubert, A., Zugazagoitia, J., Zhang, J., …, & Shen, L. (2025). Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials. Cancer Communications, 45(11), 1500-1512. https://doi.org/10.1002/cac2.70056

Vancouver

Li J, Deng T, Gu Y, Calles Blanco A, Li Z, Bai C, et al. Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials. Cancer Communications. 2025;45(11):1500-1512. doi:10.1002/cac2.70056

BibTeX
@article{Li2025,
  author = {Li, Jian and Deng, Ting and Gu, Yanhong and Calles Blanco, Antonio and Li, Zhihua and Bai, Chunmei and Wu, Lin and Huang, Jing and Li, Xingya and Yao, Yu and Song, Zhengbo and Li, Yongsheng and Liu, Lian and Xing, Ligang and Wu, Wenming and Martínez-Pérez, Julia and Hubert, Ayala and Zugazagoitia, Jon and Zhang, Jian and Wang, Yongsheng and Zhao, Yanqiu and Wen, Guilan and Xia, Guohao and Zhong, Diansheng and Chen, Xueqin and Jiang, Kuirong and Wang-Gillam, Andrea and Ding, Yuli and Liu, Sumei and Rao, Zhiyue and Liu, Xinghu and Shen, Lin},
  title = {Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials},
  journal = {Cancer Communications},
  year = {2025},
  volume = {45},
  number = {11},
  pages = {1500--1512},
  doi = {10.1002/cac2.70056}
}
Kostenlos starten →